Navigation Links
BioMS Medical Announces 2008 Year End Results
Date:3/17/2009

and development expenses for the year ended December 31, 2008 totaled $46.5 million compared with $38.9 million in 2007. Research and development expenses were $13.9 million for the three months ended December 31, 2008 compared to $9.3 million for the same quarter the previous year. The increase in expenses was the net result of: achieving full enrolment of clinical sites and patients in the MAESTRO-03 trial; increased costs for the MAESTRO-02 trial as patients enter the trial; reduced costs of the MAESTRO-01 and MINDSET-01 trials as more patients complete these trials; a decrease in drug manufacturing expenses as the manufacture of validation batches is completed; a licensing bonus payment related to the Agreement with Lilly, and; additional expenses related to alliance management and support.

At December 31, 2008, cash and cash equivalents and short-term investments totaled $90.4 million as compared to $37.9 million at December 31, 2007. At December 31, 2008, the Company had working capital of $81.3 million as compared to $32.8 million at December 31, 2007. Management estimates that the current working capital is sufficient for the Company to meet its obligations in respect of the currently initiated clinical trials.

As at December 31, 2008 there were 91,009,323 Class "A" common shares of the Company issued and outstanding.

    About BioMS Medical Corp.
    -------------------------

BioMS Medical is a biotechnology company engaged in the development and commercialization of novel therapeutic technologies. BioMS Medical's lead technology, dirucotide, is for the treatment of multiple sclerosis and is being evaluated in two pivotal phase III clinical trials for Secondary Progressive MS patients, MAESTRO-01 in Canada and Europe and MAESTRO-03 in the United States. In December 2007, BioMS entered into a licensing and development agreement granting Eli Lilly and Company exclusive worldwide rights to dirucotide in exchan
'/>"/>

SOURCE BioMS Medical Corp.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related biology technology :

1. BioMS Medical warrant extension
2. BioMS Medical to present at BIO CEO and Investor Conference
3. BioMS Medical reports results of exploratory phase II trial of dirucotide in relapsing remitting multiple sclerosis
4. BioMS Medical recognized at Scrip Awards 2008
5. BioMS Medical Announces Third Quarter 2008 Results
6. BioMS Medical to present at Rodman and Renshaw Annual Healthcare Conference
7. BioMS Medicals relapsing-remitting multiple sclerosis trial receives positive review from Data Safety Monitoring Board
8. BioMS Medicals phase III U.S. multiple sclerosis trial receives positive safety review from Data Safety Monitoring Board
9. BioMS Medical announces receipt of milestone payment from Eli Lilly and Company
10. BioMS Medical to present at Sachs Associates Biotech in Europe Forum
11. BioMS Medical to present at UBS Global Life Sciences Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/31/2014)... October 31, 2014 Stronger investment ... construction, finance and consumer electronics will help fuel ... industry research firm IBISWorld has added a report ... growing industry report collection. , The Biometrics Scan ... biometric technologies such as fingerprint, iris, retina and ...
(Date:10/30/2014)... 2014  Ardelyx, Inc. (NASDAQ: ARDX ... gastrointestinal and metabolic diseases, today announced that it ... Thursday, November 6, 2014. Following the announcement, the ... call and webcast at 4:30pm ET to review ... update. The live webcast can be ...
(Date:10/30/2014)... Rancho BioSciences , the scientific data ... public data source TCGA for several of ... is now available for other oncology groups. ... data sources for their Pharma, Government and academic clients ... that becomes more easily accessible. Rancho advises their ...
(Date:10/30/2014)... Ras Al Khaimah, UAE (PRWEB) October 30, 2014 ... the appointment of Dr. James A. Manganello, Chairman of the ... (NSCEC) of The Bahamas. The appointment was made by ... The Bahamas on September 24th, 2014. , More ... Cell Therapy and Research Bill , Prime Minister Perry Christie ...
Breaking Biology Technology:Biometrics Scan Software in the US Industry Market Research Report Now Available from IBISWorld 2Biometrics Scan Software in the US Industry Market Research Report Now Available from IBISWorld 3Ardelyx to Report Third Quarter 2014 Financial Results on November 6, 2014 2Rancho BioSciences Manually Curated TCGA Data Sets Available 2Grace Century’s Stem Cell Biobank Project Announces Chairman’s Appointment to National Stem Cell Ethics Committee of The Bahamas 2Grace Century’s Stem Cell Biobank Project Announces Chairman’s Appointment to National Stem Cell Ethics Committee of The Bahamas 3
... (EMBL) discovered a new way to make use of drugs, ... how similar the side effects of different drugs are and ... molecule. The study, published in Science this week, ... often share target proteins, modes of action and unpleasant side ...
... ATRC ), a medical device company and a leader ... the second,quarter ended June 30, 2008 on Tuesday, August 5, ... a.m. ET on Tuesday,August 5, 2008 to discuss second quarter ... be available online from the investor relations,page of AtriCure,s corporate ...
... increased 38% to $42.3 million ... income rose 30% to $14.2 million, SHANGHAI, ... Board: CHBT) ("China-Biotics", "the,Company"), a leading Chinese firm ... of probiotics products,today announced its financial results for ...
Cached Biology Technology:Teaching old drugs new tricks 2AtriCure Announces Web Cast and Conference Call of Second Quarter 2008 Financial Results 2China-Biotics, Inc. Reports Fourth Quarter and Full Year Fiscal 2008 Financial Results 2China-Biotics, Inc. Reports Fourth Quarter and Full Year Fiscal 2008 Financial Results 3China-Biotics, Inc. Reports Fourth Quarter and Full Year Fiscal 2008 Financial Results 4China-Biotics, Inc. Reports Fourth Quarter and Full Year Fiscal 2008 Financial Results 5China-Biotics, Inc. Reports Fourth Quarter and Full Year Fiscal 2008 Financial Results 6China-Biotics, Inc. Reports Fourth Quarter and Full Year Fiscal 2008 Financial Results 7China-Biotics, Inc. Reports Fourth Quarter and Full Year Fiscal 2008 Financial Results 8China-Biotics, Inc. Reports Fourth Quarter and Full Year Fiscal 2008 Financial Results 9China-Biotics, Inc. Reports Fourth Quarter and Full Year Fiscal 2008 Financial Results 10China-Biotics, Inc. Reports Fourth Quarter and Full Year Fiscal 2008 Financial Results 11China-Biotics, Inc. Reports Fourth Quarter and Full Year Fiscal 2008 Financial Results 12China-Biotics, Inc. Reports Fourth Quarter and Full Year Fiscal 2008 Financial Results 13
(Date:10/31/2014)... a new test that can distinguish between birds that ... influenza virus or "bird flu" with those that have ... in the fight against this often fatal strain of ... of South East Asia, particularly Indonesia and Vietnam. , ... to humans and the threat of a pandemic if ...
(Date:10/31/2014)... , Oct. 30, 2014  HITLAB SM ... pleased to announce its inaugural HITLAB Innovators Summit ... University,s Low Library. HITLAB will partner with the ... Wellness, Blueprint Health, ProtoHack, Columbia Business School Alumni ... and Columbia Industrial Engineering and Operations Research, bringing ...
(Date:10/30/2014)... a $1.04 million grant from the U.S. Army ... osteoarthritis using a patient,s own stem cells, spurred ... polymers., Liping Tang, a bioengineering professor and interim ... is primarily focused on helping soldiers who are ... if we inject microscaffolding that we,ve developed into ...
Breaking Biology News(10 mins):New step towards eradication of H5N1 bird flu 2HITLAB Announces Inaugural HITLAB Innovators Summit 2HITLAB Announces Inaugural HITLAB Innovators Summit 3UTA researcher uses microscaffolding injections to mend cartilage, prevent osteoarthritis 2
... medication robbed Elma Phifer of her vision two decades ago ... reduced the ability of her eyes to soothe their damaged ... family and friends to help her do many of the ... twenty years and several life milestones later, Elma is able ...
... share a genetic profile that appears to be unique ... researchers at Cincinnati Children's Hospital Medical Center. The discovery ... specifically tailored to children who suffer from the severest ... Feb. 10 issue of the Journal of Allergy and ...
... throw a wrench in the transmissions of several speed demons ... Medicine in St. Louis and Harvard University have identified a ... slow cell invasion by malaria and other parasites known as ... March 15 issue of Proceedings of the National Academy of ...
Cached Biology News:Artifical cornea lets woman blind 20 years see 2Artifical cornea lets woman blind 20 years see 3Artifical cornea lets woman blind 20 years see 4Asthma gene clusters identified 2Asthma gene clusters identified 3Protein offers way to stop microscopic parasites in their tracks 2Protein offers way to stop microscopic parasites in their tracks 3
PMM2 Immunogen: PMM2 (NP_000294, 47 a.a. ~ 112 a.a) partial recombinant protein with GST tag. Storage: -20 C, Avoid Freeze/Thaw Cycles *Available for distribution in the US only...
HOXC11 Antibody...
Rabbit polyclonal to Raf1 ( Abpromise for all tested applications). entrezGeneID: 5894 SwissProtID: P04049...
Sheep polyclonal to hCG beta core fragment ( Abpromise for all tested applications). Antigen: Full length native protein (purified) from human urine. Entrez GeneID: 1082 Swiss Protein ID...
Biology Products: